Invasive Pneumococcal Disease in England and Wales: Vaccination Implications
Identifieur interne : 002B07 ( Main/Corpus ); précédent : 002B06; suivant : 002B08Invasive Pneumococcal Disease in England and Wales: Vaccination Implications
Auteurs : Karen Sleeman ; Kyle Knox ; Robert George ; Elizabeth Miller ; Pauline Waight ; David Griffiths ; A. Efstratiou ; K. Broughton ; Richard T. Mayon-White ; E. R. Moxon ; D. W. CrookSource :
- The Journal of Infectious Diseases [ 0022-1899 ] ; 2001-01-15.
Abstract
Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants <1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children <5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.
Url:
DOI: 10.1086/317924
Links to Exploration step
ISTEX:A537318E0F71390E700C35674347C8F8746844B8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title><author><name sortKey="Sleeman, Karen" sort="Sleeman, Karen" uniqKey="Sleeman K" first="Karen" last="Sleeman">Karen Sleeman</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation></author><author><name sortKey="Knox, Kyle" sort="Knox, Kyle" uniqKey="Knox K" first="Kyle" last="Knox">Kyle Knox</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation><affiliation><mods:affiliation>Wellcome Trust Centre for Epidemiology of Infectious Diseases, Oxford University, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="George, Robert" sort="George, Robert" uniqKey="George R" first="Robert" last="George">Robert George</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Miller, Elizabeth" sort="Miller, Elizabeth" uniqKey="Miller E" first="Elizabeth" last="Miller">Elizabeth Miller</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Waight, Pauline" sort="Waight, Pauline" uniqKey="Waight P" first="Pauline" last="Waight">Pauline Waight</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Griffiths, David" sort="Griffiths, David" uniqKey="Griffiths D" first="David" last="Griffiths">David Griffiths</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation></author><author><name sortKey="Efstratiou, A" sort="Efstratiou, A" uniqKey="Efstratiou A" first="A." last="Efstratiou">A. Efstratiou</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Broughton, K" sort="Broughton, K" uniqKey="Broughton K" first="K." last="Broughton">K. Broughton</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Mayon White, Richard T" sort="Mayon White, Richard T" uniqKey="Mayon White R" first="Richard T." last="Mayon-White">Richard T. Mayon-White</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Moxon, E R" sort="Moxon, E R" uniqKey="Moxon E" first="E. R." last="Moxon">E. R. Moxon</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation></author><author><name sortKey="Crook, D W" sort="Crook, D W" uniqKey="Crook D" first="D. W." last="Crook">D. W. Crook</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: dcrook@molbiol.ox.ac.uk</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A537318E0F71390E700C35674347C8F8746844B8</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1086/317924</idno><idno type="url">https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002B07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title><author><name sortKey="Sleeman, Karen" sort="Sleeman, Karen" uniqKey="Sleeman K" first="Karen" last="Sleeman">Karen Sleeman</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation></author><author><name sortKey="Knox, Kyle" sort="Knox, Kyle" uniqKey="Knox K" first="Kyle" last="Knox">Kyle Knox</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation><affiliation><mods:affiliation>Wellcome Trust Centre for Epidemiology of Infectious Diseases, Oxford University, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="George, Robert" sort="George, Robert" uniqKey="George R" first="Robert" last="George">Robert George</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Miller, Elizabeth" sort="Miller, Elizabeth" uniqKey="Miller E" first="Elizabeth" last="Miller">Elizabeth Miller</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Waight, Pauline" sort="Waight, Pauline" uniqKey="Waight P" first="Pauline" last="Waight">Pauline Waight</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Griffiths, David" sort="Griffiths, David" uniqKey="Griffiths D" first="David" last="Griffiths">David Griffiths</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation></author><author><name sortKey="Efstratiou, A" sort="Efstratiou, A" uniqKey="Efstratiou A" first="A." last="Efstratiou">A. Efstratiou</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Broughton, K" sort="Broughton, K" uniqKey="Broughton K" first="K." last="Broughton">K. Broughton</name><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Mayon White, Richard T" sort="Mayon White, Richard T" uniqKey="Mayon White R" first="Richard T." last="Mayon-White">Richard T. Mayon-White</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation><affiliation><mods:affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Moxon, E R" sort="Moxon, E R" uniqKey="Moxon E" first="E. R." last="Moxon">E. R. Moxon</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation></author><author><name sortKey="Crook, D W" sort="Crook, D W" uniqKey="Crook D" first="D. W." last="Crook">D. W. Crook</name><affiliation><mods:affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: dcrook@molbiol.ox.ac.uk</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Infectious Diseases</title><title level="j" type="abbrev">The Journal of Infectious Diseases</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="2001-01-15">2001-01-15</date><biblScope unit="volume">183</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="239">239</biblScope><biblScope unit="page" to="246">246</biblScope></imprint><idno type="ISSN">0022-1899</idno></series><idno type="istex">A537318E0F71390E700C35674347C8F8746844B8</idno><idno type="DOI">10.1086/317924</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants <1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children <5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Karen Sleeman</name><affiliations><json:string>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</json:string></affiliations></json:item><json:item><name>Kyle Knox</name><affiliations><json:string>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</json:string><json:string>Wellcome Trust Centre for Epidemiology of Infectious Diseases, Oxford University, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Robert George</name><affiliations><json:string>Public Health Laboratory Service, Colindale, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Elizabeth Miller</name><affiliations><json:string>Public Health Laboratory Service, Colindale, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Pauline Waight</name><affiliations><json:string>Public Health Laboratory Service, Colindale, London, United Kingdom</json:string></affiliations></json:item><json:item><name>David Griffiths</name><affiliations><json:string>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</json:string></affiliations></json:item><json:item><name>A. Efstratiou</name><affiliations><json:string>Public Health Laboratory Service, Colindale, London, United Kingdom</json:string></affiliations></json:item><json:item><name>K. Broughton</name><affiliations><json:string>Public Health Laboratory Service, Colindale, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Richard T. Mayon-White</name><affiliations><json:string>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</json:string><json:string>Public Health Laboratory Service, Colindale, London, United Kingdom</json:string></affiliations></json:item><json:item><name>E. R. Moxon</name><affiliations><json:string>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</json:string></affiliations></json:item><json:item><name>on Behalf of the Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group D. W. Crook</name><affiliations><json:string>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</json:string><json:string>E-mail: dcrook@molbiol.ox.ac.uk</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Major Articles</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants >1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children >5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.</abstract><qualityIndicators><score>6.596</score><pdfVersion>1.2</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>839</abstractCharCount><pdfWordCount>5159</pdfWordCount><pdfCharCount>33467</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>133</abstractWordCount></qualityIndicators><title>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title><genre><json:string>research-article</json:string></genre><host><volume>183</volume><pages><last>246</last><first>239</first></pages><issn><json:string>0022-1899</json:string></issn><issue>2</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1537-6613</json:string></eissn><title>The Journal of Infectious Diseases</title></host><categories><wos><json:string>IMMUNOLOGY</json:string><json:string>INFECTIOUS DISEASES</json:string><json:string>MICROBIOLOGY</json:string></wos></categories><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1086/317924</json:string></doi><id>A537318E0F71390E700C35674347C8F8746844B8</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>The University of Chicago Press</publisher><availability><p>OUP</p></availability><date>2001</date></publicationStmt><notesStmt><note>Members of the Oxford Pneumococcal Surveillance Group are listed after the text.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title><author><persName><forename type="first">Karen</forename><surname>Sleeman</surname></persName><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation></author><author><persName><forename type="first">Kyle</forename><surname>Knox</surname></persName><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation><affiliation>Wellcome Trust Centre for Epidemiology of Infectious Diseases, Oxford University, London, United Kingdom</affiliation></author><author><persName><forename type="first">Robert</forename><surname>George</surname></persName><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation></author><author><persName><forename type="first">Elizabeth</forename><surname>Miller</surname></persName><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation></author><author><persName><forename type="first">Pauline</forename><surname>Waight</surname></persName><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation></author><author><persName><forename type="first">David</forename><surname>Griffiths</surname></persName><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation></author><author><persName><forename type="first">A.</forename><surname>Efstratiou</surname></persName><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation></author><author><persName><forename type="first">K.</forename><surname>Broughton</surname></persName><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation></author><author><persName><forename type="first">Richard T.</forename><surname>Mayon-White</surname></persName><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation></author><author><persName><forename type="first">E. R.</forename><surname>Moxon</surname></persName><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation></author><author corresp="yes"><persName><forename type="first">D. W.</forename><surname>Crook</surname></persName><email>dcrook@molbiol.ox.ac.uk</email><note type="biography">a Members of the Oxford Pneumococcal Surveillance Group are listed after the text.</note><affiliation>a Members of the Oxford Pneumococcal Surveillance Group are listed after the text.</affiliation><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation></author></analytic><monogr><title level="j">The Journal of Infectious Diseases</title><title level="j" type="abbrev">The Journal of Infectious Diseases</title><idno type="pISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="2001-01-15"></date><biblScope unit="volume">183</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="239">239</biblScope><biblScope unit="page" to="246">246</biblScope></imprint></monogr><idno type="istex">A537318E0F71390E700C35674347C8F8746844B8</idno><idno type="DOI">10.1086/317924</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants <1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children <5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.</p></abstract></profileDesc><revisionDesc><change when="2001-01-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">jinfdis</journal-id><journal-id journal-id-type="publisher-id">jid</journal-id><journal-title>The Journal of Infectious Diseases</journal-title><abbrev-journal-title>The Journal of Infectious Diseases</abbrev-journal-title><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn><publisher><publisher-name>The University of Chicago Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1086/317924</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Articles</subject></subj-group></article-categories><title-group><article-title>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sleeman</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Knox</surname><given-names>Kyle</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Waight</surname><given-names>Pauline</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Griffiths</surname><given-names>David</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Efstratiou</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Broughton</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mayon-White</surname><given-names>Richard T.</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moxon</surname><given-names>E. R.</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Crook</surname><given-names>D. W.</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref rid="cor1" ref-type="corresp"></xref><on-behalf-of>on Behalf of the Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</on-behalf-of><xref rid="FN1" ref-type="author-notes"><sup>a</sup></xref></contrib><aff id="AFF1"><sup>1</sup><institution>Oxford Vaccine Group, John Radcliffe Hospital</institution>, <addr-line>Oxford</addr-line></aff><aff id="AFF2"><sup>2</sup><institution>Wellcome Trust Centre for Epidemiology of Infectious Diseases, Oxford University</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff><aff id="AFF3"><sup>3</sup><institution>Public Health Laboratory Service</institution>, <addr-line>Colindale, London</addr-line>, <country>United Kingdom</country></aff></contrib-group><author-notes><corresp id="cor1">Reprints or correspondence: Dr. Derrick Crook, Dept. of Microbiology, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom (<email>dcrook@molbiol.ox.ac.uk</email>).</corresp><fn id="FN1" fn-type="other"><label>a</label><p>Members of the Oxford Pneumococcal Surveillance Group are listed after the text.</p></fn></author-notes><pub-date pub-type="ppub"><day>15</day><month>1</month><year>2001</year></pub-date><volume>183</volume><issue>2</issue><fpage>239</fpage><lpage>246</lpage><history><date date-type="received"><day>22</day><month>6</month><year>2000</year></date><date date-type="rev-recd"><day>13</day><month>9</month><year>2000</year></date></history><copyright-statement>© 2001 by the Infectious Diseases Society of America</copyright-statement><copyright-year>2001</copyright-year><abstract><p>Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants <1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children <5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title></titleInfo><name type="personal"><namePart type="given">Karen</namePart><namePart type="family">Sleeman</namePart><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kyle</namePart><namePart type="family">Knox</namePart><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation><affiliation>Wellcome Trust Centre for Epidemiology of Infectious Diseases, Oxford University, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert</namePart><namePart type="family">George</namePart><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elizabeth</namePart><namePart type="family">Miller</namePart><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pauline</namePart><namePart type="family">Waight</namePart><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Griffiths</namePart><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Efstratiou</namePart><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Broughton</namePart><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard T.</namePart><namePart type="family">Mayon-White</namePart><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation><affiliation>Public Health Laboratory Service, Colindale, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E. R.</namePart><namePart type="family">Moxon</namePart><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart>on Behalf of the Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</namePart><namePart type="given">D. W.</namePart><namePart type="family">Crook</namePart><affiliation>Oxford Vaccine Group, John Radcliffe Hospital, Oxford</affiliation><affiliation>E-mail: dcrook@molbiol.ox.ac.uk</affiliation><description>a Members of the Oxford Pneumococcal Surveillance Group are listed after the text.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">2001-01-15</dateIssued><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants <1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children <5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.</abstract><note type="footnotes">Members of the Oxford Pneumococcal Surveillance Group are listed after the text.</note><relatedItem type="host"><titleInfo><title>The Journal of Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>The Journal of Infectious Diseases</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0022-1899</identifier><identifier type="eISSN">1537-6613</identifier><identifier type="PublisherID">jid</identifier><identifier type="PublisherID-hwp">jinfdis</identifier><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>183</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>239</start><end>246</end></extent></part></relatedItem><identifier type="istex">A537318E0F71390E700C35674347C8F8746844B8</identifier><identifier type="DOI">10.1086/317924</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2001 by the Infectious Diseases Society of America</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><original>true</original><mimetype>image/tiff</mimetype><extension>tiff</extension><uri>https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/covers/tiff</uri></json:item></covers><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/annexes/jpeg</uri></json:item><json:item><original>true</original><mimetype>image/gif</mimetype><extension>gif</extension><uri>https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/annexes/gif</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/A537318E0F71390E700C35674347C8F8746844B8/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">IMMUNOLOGY</classCode><classCode scheme="WOS">INFECTIOUS DISEASES</classCode><classCode scheme="WOS">MICROBIOLOGY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002B07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:A537318E0F71390E700C35674347C8F8746844B8
|texte= Invasive Pneumococcal Disease in England and Wales: Vaccination Implications
}}
| This area was generated with Dilib version V0.6.23. |  |